Provided by Tiger Trade Technology Pte. Ltd.

Oncolytics Biotech Inc

0.9896
+0.01281.31%
Post-market: 0.9892-0.0004-0.04%19:59 EST
Volume:392.31K
Turnover:383.39K
Market Cap:104.90M
PE:-3.47
High:0.9970
Open:0.9863
Low:0.9601
Close:0.9768
52wk High:1.51
52wk Low:0.3258
Shares:106.00M
Float Shares:93.63M
Volume Ratio:0.56
T/O Rate:0.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2855
EPS(LYR):-0.2881
ROE:-769.06%
ROA:-111.21%
PB:1258.27
PE(LYR):-3.43

Loading ...

Company Profile

Company Name:
Oncolytics Biotech Inc
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
28
Office Location:
322 11th Avenue SW,Suite 804,Calgary,Alberta,Canada
Zip Code:
T2R 0C5
Fax:
403 283 0858
Introduction:
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Directors

Name
Position
Matthew C. Coffey
President and Chief Executive Officer and Director
Wayne Pisano
Chair of the Board
Angela Holtham
Director
Bernd R. Seizinger
Director
Deborah M. Brown
Director
Leonard Kruimer
Director
William G. Rice
Director

Shareholders

Name
Position
Matthew C. Coffey
President and Chief Executive Officer and Director
Kirk J. Look
Chief Financial Officer
Allison Hagerman
Vice President, Product Development
Andrew de Guttadauro
Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc.
Thomas C. Heineman
Global Head of Clinical Development and Operations